You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

Article metrics

Article menu
XML
Health economics
Original research
Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

 

Online download statistics by month:

Online download statistics by month: August 2021 to June 2025

AbstractFullPdf
Aug 2021499498131
Sep 202111011469
Oct 2021908647
Nov 2021858554
Dec 202131531749
Jan 202212011524
Feb 2022605830
Mar 2022525515
Apr 2022646515
May 2022484920
Jun 2022262215
Jul 2022282310
Aug 2022433818
Sep 2022252312
Oct 2022312723
Nov 2022514220
Dec 202221198
Jan 2023383218
Feb 2023242315
Mar 2023252310
Apr 202328217
May 2023272211
Jun 202323225
Jul 2023211816
Aug 2023191612
Sep 202321187
Oct 202313115
Nov 202326249
Dec 2023252514
Jan 2024272611
Feb 202418135
Mar 2024212233
Apr 2024312812
May 2024434119
Jun 2024272714
Jul 2024161620
Aug 2024484521
Sep 202420217
Oct 2024272324
Nov 2024242316
Dec 2024262521
Jan 2025433913
Feb 2025978913
Mar 2025302919
Apr 2025312931
May 2025252513
Jun 2025771
Total25192419982